Totus Medicines is a company.
Totus Medicines has raised $106.0M across 2 funding rounds.
Key people at Totus Medicines.
Totus Medicines has raised $106.0M in total across 2 funding rounds.
Totus Medicines has raised $106.0M in total across 2 funding rounds.
Totus Medicines's investors include Zachary Bogue, DCVC (Data Collective), Dimension Capital, Pivotal bioVenture Partners, The Column Group.
Totus Medicines is a biotechnology company developing precision oral medicines to target "undruggable" proteins across the human genome, addressing diseases like cancers and heart conditions where 90% of potential targets have historically lacked viable drugs.[1][2] Its high-throughput platform combines covalent chemistry, ultra-high-throughput cell-based screening, and AI/ML-powered drug design to discover drugs at unprecedented volume, speed, and efficiency, with a lead product TOS-358 (a PI3Kα inhibitor) in Phase 1 trials for solid tumors such as squamous cell carcinoma of the head and neck.[1][2][3] The company serves patients with limited treatment options in oncology, immunology, and inflammation, solving the core problem of undruggable targets by building a growing, searchable catalog of precision therapies; it has raised $40M in a Series A round in December 2021 and employs 11-50 people in Emeryville, CA.[1]
Founded in 2019 (with some sources noting 2020), Totus Medicines emerged from the recognition that while researchers identify hundreds of disease targets daily, 90% remain undruggable, prompting the creation of its revolutionary platform to unlock them.[1][2][5] The team consists of cross-disciplinary scientists and professionals focused on bringing hope to every diagnosis, though specific founders are not detailed in available data; early efforts prioritized untreatable diseases like specific cancers and heart conditions.[1][2][4] Pivotal early traction includes securing $40M in Series A funding in December 2021 and advancing TOS-358 to Phase 1 clinical trials by 2023, alongside discovery-stage programs like AKT inhibitors for neoplasms.[1][3]
Totus Medicines rides the wave of precision medicine and AI-driven drug discovery, capitalizing on advances in covalent chemistry—proven in historic drugs like penicillin and oncology therapies—to tackle the 90% of the genome deemed undruggable.[2] Timing aligns with surging biotech investment in genomic-scale platforms amid rising cancer prevalence and demand for targeted therapies, amplified by AI/ML efficiencies that accelerate R&D amid patent cliffs for blockbusters.[1][2] Market forces like regulatory support for orphan drugs and oncology innovation favor Totus, positioning it to influence the ecosystem by democratizing access to novel targets and fostering a knowledge base for future precision drugs.[1][2]
Totus Medicines is poised to expand its pipeline beyond TOS-358, with recent press releases (e.g., January 2025) signaling momentum in oncology and immunology programs, potentially advancing more assets to clinic amid AI-enhanced discovery.[2] Trends like covalent drug resurgence and genomic mapping will shape its path, enabling broader ecosystem impact through partnerships or an eventual IPO, as hinted in pre-IPO tracking.[5] Its influence could evolve from pioneer to platform leader, transforming undruggable targets into treatable ones and redefining biotech scalability—ultimately making the entire human genome druggable as promised.[1][2]
Key people at Totus Medicines.
Totus Medicines has raised $106.0M across 2 funding rounds. Most recently, it raised $66.0M Series B in December 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2023 | $66.0M Series B | Zachary Bogue, DCVC (Data Collective), Dimension Capital, Pivotal bioVenture Partners, The Column Group | |
| Dec 1, 2021 | $40.0M Series A | DCVC (Data Collective) |
